annual EBIT:
-$580.11M-$391.94M(-208.30%)Summary
- As of today (May 29, 2025), ARWR annual earnings before interest & taxes is -$580.11 million, with the most recent change of -$391.94 million (-208.30%) on September 30, 2024.
- During the last 3 years, ARWR annual EBIT has fallen by -$439.26 million (-311.87%).
- ARWR annual EBIT is now -1048.03% below its all-time high of $61.19 million, reached on September 30, 2019.
Performance
ARWR EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
$391.25M+$544.72M(+354.94%)Summary
- As of today (May 29, 2025), ARWR quarterly earnings before interest & taxes is $391.25 million, with the most recent change of +$544.72 million (+354.94%) on March 31, 2025.
- Over the past year, ARWR quarterly EBIT has increased by +$511.01 million (+426.72%).
- ARWR quarterly EBIT is now at all-time high.
Performance
ARWR quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$89.25M+$511.01M(+85.13%)Summary
- As of today (May 29, 2025), ARWR TTM earnings before interest & taxes is -$89.25 million, with the most recent change of +$511.01 million (+85.13%) on March 31, 2025.
- Over the past year, ARWR TTM EBIT has increased by +$365.78 million (+80.39%).
- ARWR TTM EBIT is now -245.85% below its all-time high of $61.19 million, reached on September 30, 2019.
Performance
ARWR TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ARWR EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -208.3% | +426.7% | +80.4% |
| 3 y3 years | -311.9% | +781.9% | +17.0% |
| 5 y5 years | -1048.0% | +1859.2% | -7921.2% |
ARWR EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -311.9% | at low | at high | +331.7% | at high | +85.1% |
| 5 y | 5-year | -1048.0% | at low | at high | +331.7% | -7921.2% | +85.1% |
| alltime | all time | -1048.0% | at low | at high | +331.7% | -245.8% | +85.1% |
ARWR EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $391.25M(-354.9%) | -$89.25M(-85.1%) |
| Dec 2024 | - | -$153.47M(-3.0%) | -$600.25M(+3.5%) |
| Sep 2024 | -$580.11M(+208.3%) | -$158.15M(-6.4%) | -$580.11M(+10.4%) |
| Jun 2024 | - | -$168.88M(+41.0%) | -$525.68M(+15.5%) |
| Mar 2024 | - | -$119.75M(-10.2%) | -$455.03M(+61.0%) |
| Dec 2023 | - | -$133.32M(+28.5%) | -$282.54M(+50.2%) |
| Sep 2023 | -$188.16M(+8.9%) | -$103.73M(+5.6%) | -$188.16M(+12.9%) |
| Jun 2023 | - | -$98.22M(-286.3%) | -$166.59M(+18.6%) |
| Mar 2023 | - | $52.73M(-235.4%) | -$140.41M(-5.6%) |
| Dec 2022 | - | -$38.95M(-52.6%) | -$148.78M(-14.1%) |
| Sep 2022 | -$172.71M(+22.6%) | -$82.16M(+14.0%) | -$173.16M(+17.2%) |
| Jun 2022 | - | -$72.05M(-262.4%) | -$147.69M(+37.4%) |
| Mar 2022 | - | $44.37M(-170.1%) | -$107.52M(-40.3%) |
| Dec 2021 | - | -$63.32M(+11.7%) | -$180.11M(+27.9%) |
| Sep 2021 | -$140.85M(+51.2%) | -$56.69M(+77.9%) | -$140.85M(+4.9%) |
| Jun 2021 | - | -$31.87M(+12.9%) | -$134.27M(+13.5%) |
| Mar 2021 | - | -$28.23M(+17.4%) | -$118.35M(+5.3%) |
| Dec 2020 | - | -$24.05M(-52.0%) | -$112.36M(+20.6%) |
| Sep 2020 | -$93.16M(-252.2%) | -$50.12M(+214.3%) | -$93.16M(+178.9%) |
| Jun 2020 | - | -$15.95M(-28.3%) | -$33.40M(-3027.1%) |
| Mar 2020 | - | -$22.24M(+358.3%) | $1.14M(-97.5%) |
| Dec 2019 | - | -$4.85M(-150.4%) | $45.39M(-25.8%) |
| Sep 2019 | $61.19M(-209.4%) | $9.64M(-48.2%) | $61.19M(+51.5%) |
| Jun 2019 | - | $18.60M(-15.5%) | $40.38M(+588.2%) |
| Mar 2019 | - | $22.01M(+101.1%) | $5.87M(-118.8%) |
| Dec 2018 | - | $10.95M(-198.0%) | -$31.18M(-44.3%) |
| Sep 2018 | -$55.94M(+51.2%) | -$11.17M(-29.8%) | -$55.94M(+1.7%) |
| Jun 2018 | - | -$15.92M(+5.9%) | -$55.02M(+22.8%) |
| Mar 2018 | - | -$15.03M(+8.8%) | -$44.81M(+24.8%) |
| Dec 2017 | - | -$13.81M(+34.8%) | -$35.91M(-2.9%) |
| Sep 2017 | -$37.00M(-53.6%) | -$10.25M(+79.4%) | -$37.00M(-20.4%) |
| Jun 2017 | - | -$5.71M(-6.8%) | -$46.49M(-22.7%) |
| Mar 2017 | - | -$6.13M(-58.9%) | -$60.12M(-20.1%) |
| Dec 2016 | - | -$14.90M(-24.5%) | -$75.25M(-5.6%) |
| Sep 2016 | -$79.69M(-17.0%) | -$19.74M(+2.1%) | -$79.69M(-6.4%) |
| Jun 2016 | - | -$19.34M(-9.0%) | -$85.18M(+4.1%) |
| Mar 2016 | - | -$21.26M(+9.9%) | -$81.83M(-9.3%) |
| Dec 2015 | - | -$19.34M(-23.3%) | -$90.20M(-6.0%) |
| Sep 2015 | -$95.97M(+87.8%) | -$25.23M(+57.7%) | -$95.97M(+5.6%) |
| Jun 2015 | - | -$15.99M(-46.0%) | -$90.92M(+3.8%) |
| Mar 2015 | - | -$29.63M(+18.0%) | -$87.63M(+26.6%) |
| Dec 2014 | - | -$25.12M(+24.4%) | -$69.21M(+35.4%) |
| Sep 2014 | -$51.10M(+119.5%) | -$20.18M(+58.9%) | -$51.10M(+31.3%) |
| Jun 2014 | - | -$12.70M(+13.3%) | -$38.92M(+24.3%) |
| Mar 2014 | - | -$11.21M(+60.0%) | -$31.30M(+22.8%) |
| Dec 2013 | - | -$7.01M(-12.4%) | -$25.48M(+9.4%) |
| Sep 2013 | -$23.28M(+10.4%) | -$8.00M(+57.4%) | -$23.28M(+12.7%) |
| Jun 2013 | - | -$5.08M(-5.7%) | -$20.66M(-7.7%) |
| Mar 2013 | - | -$5.39M(+12.1%) | -$22.38M(+2.4%) |
| Dec 2012 | - | -$4.81M(-10.6%) | -$21.86M(+3.7%) |
| Sep 2012 | -$21.09M | -$5.38M(-20.9%) | -$21.09M(+13.2%) |
| Jun 2012 | - | -$6.80M(+39.7%) | -$18.62M(+37.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$4.87M(+20.5%) | -$13.59M(+29.0%) |
| Dec 2011 | - | -$4.04M(+38.7%) | -$10.53M(+7.2%) |
| Sep 2011 | -$9.83M(+68.5%) | -$2.91M(+64.5%) | -$9.83M(+13.0%) |
| Jun 2011 | - | -$1.77M(-2.3%) | -$8.70M(+4.5%) |
| Mar 2011 | - | -$1.81M(-45.7%) | -$8.32M(+112.5%) |
| Dec 2010 | - | -$3.34M(+86.9%) | -$3.92M(+42.9%) |
| Sep 2010 | -$5.83M(-70.2%) | -$1.79M(+28.3%) | -$2.74M(-38.3%) |
| Jun 2010 | - | -$1.39M(-153.6%) | -$4.44M(-17.1%) |
| Mar 2010 | - | $2.60M(-220.1%) | -$5.35M(-59.3%) |
| Dec 2009 | - | -$2.16M(-38.0%) | -$13.14M(-32.8%) |
| Sep 2009 | -$19.56M(-44.1%) | -$3.48M(+51.2%) | -$19.56M(-29.2%) |
| Jun 2009 | - | -$2.30M(-55.6%) | -$27.63M(-21.6%) |
| Mar 2009 | - | -$5.19M(-39.4%) | -$35.23M(-5.1%) |
| Dec 2008 | - | -$8.58M(-25.8%) | -$37.10M(+4.8%) |
| Sep 2008 | -$35.00M(-7.8%) | -$11.56M(+16.8%) | -$35.41M(-0.2%) |
| Jun 2008 | - | -$9.90M(+39.9%) | -$35.50M(-9.0%) |
| Mar 2008 | - | -$7.07M(+2.7%) | -$39.00M(-3.4%) |
| Dec 2007 | - | -$6.89M(-40.9%) | -$40.36M(+6.4%) |
| Sep 2007 | -$37.95M(+85.3%) | -$11.64M(-13.1%) | -$37.95M(+18.0%) |
| Jun 2007 | - | -$13.40M(+58.8%) | -$32.16M(+38.1%) |
| Mar 2007 | - | -$8.44M(+88.6%) | -$23.29M(+12.0%) |
| Dec 2006 | - | -$4.47M(-23.6%) | -$20.78M(+1.8%) |
| Sep 2006 | -$20.48M(+113.5%) | -$5.85M(+29.4%) | -$20.42M(+13.3%) |
| Jun 2006 | - | -$4.52M(-23.8%) | -$18.02M(+10.5%) |
| Mar 2006 | - | -$5.93M(+44.3%) | -$16.30M(+35.4%) |
| Dec 2005 | - | -$4.11M(+19.1%) | -$12.04M(+25.4%) |
| Sep 2005 | -$9.59M(+256.5%) | -$3.45M(+23.1%) | -$9.60M(+26.9%) |
| Jun 2005 | - | -$2.81M(+68.2%) | -$7.57M(+41.2%) |
| Mar 2005 | - | -$1.67M(-0.6%) | -$5.36M(+26.9%) |
| Dec 2004 | - | -$1.68M(+18.1%) | -$4.23M(+57.1%) |
| Sep 2004 | -$2.69M(+2750.4%) | -$1.42M(+138.3%) | -$2.69M(+108.9%) |
| Jun 2004 | - | -$596.00K(+12.1%) | -$1.29M(+82.2%) |
| Mar 2004 | - | -$531.50K(+273.0%) | -$706.70K(+245.2%) |
| Dec 2003 | - | -$142.50K(+709.7%) | -$204.70K(+116.6%) |
| Sep 2003 | -$94.40K(-93.3%) | -$17.60K(+16.6%) | -$94.50K(-93.2%) |
| Jun 2003 | - | -$15.10K(-48.8%) | -$1.40M(-2.4%) |
| Mar 2003 | - | -$29.50K(-8.7%) | -$1.43M(+0.5%) |
| Dec 2002 | - | -$32.30K(-97.6%) | -$1.42M(+0.5%) |
| Sep 2002 | -$1.42M(+1232.3%) | -$1.32M(+2597.8%) | -$1.42M(+1016.0%) |
| Jun 2002 | - | -$48.90K(+118.3%) | -$126.90K(+35.7%) |
| Mar 2002 | - | -$22.40K(-12.8%) | -$93.50K(-3.2%) |
| Dec 2001 | - | -$25.70K(-14.0%) | -$96.60K(-9.1%) |
| Sep 2001 | -$106.30K(-2.7%) | -$29.90K(+92.9%) | -$106.30K(+2.1%) |
| Jun 2001 | - | -$15.50K(-39.2%) | -$104.10K(-6.9%) |
| Mar 2001 | - | -$25.50K(-28.0%) | -$111.80K(0.0%) |
| Dec 2000 | - | -$35.40K(+27.8%) | -$111.80K(+2.3%) |
| Sep 2000 | -$109.20K(+94.3%) | -$27.70K(+19.4%) | -$109.30K(+33.9%) |
| Jun 2000 | - | -$23.20K(-9.0%) | -$81.60K(+39.7%) |
| Mar 2000 | - | -$25.50K(-22.5%) | -$58.40K(+77.5%) |
| Dec 1999 | - | -$32.90K | -$32.90K |
| Sep 1999 | -$56.20K(+131.3%) | - | - |
| Sep 1998 | -$24.30K(-84.7%) | - | - |
| Sep 1997 | -$158.60K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual EBIT year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly EBIT year-on-year change?
- What is Arrowhead Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM EBIT year-on-year change?
What is Arrowhead Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of ARWR is -$580.11M
What is the all time high annual EBIT for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual earnings before interest & taxes is $61.19M
What is Arrowhead Pharmaceuticals annual EBIT year-on-year change?
Over the past year, ARWR annual earnings before interest & taxes has changed by -$391.94M (-208.30%)
What is Arrowhead Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of ARWR is $391.25M
What is the all time high quarterly EBIT for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly earnings before interest & taxes is $391.25M
What is Arrowhead Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, ARWR quarterly earnings before interest & taxes has changed by +$511.01M (+426.72%)
What is Arrowhead Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of ARWR is -$89.25M
What is the all time high TTM EBIT for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM earnings before interest & taxes is $61.19M
What is Arrowhead Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, ARWR TTM earnings before interest & taxes has changed by +$365.78M (+80.39%)